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Simocyclinone D8 (SD8) is an antibiotic produced by Streptomyces antibioticus that targets DNA gyrase. A
previous structure of SD8 complexed with the N-terminal domain of the DNA gyrase A protein (GyrA) suggested
that four SD8 molecules stabilized a tetramer of the protein; subsequent mass spectrometry experiments
suggested that a protein dimer with two symmetry-related SD8s was more likely. This work describes the
structures of a further truncated form of the GyrA N-terminal domain fragment with and without SD8 bound. The
structure with SD8 has the two SD8 molecules bound within the same GyrA dimer. This new structure is entirely
consistent with themutations in GyrA that confer SD8 resistance and, by comparison with a new apo structure of
the GyrA N-terminal domain, reveals the likely conformation changes that occur upon SD8 binding and the
detailed mechanism of SD8 inhibition of gyrase. Isothermal titration calorimetry experiments are consistent with
the crystallography results and further suggest that a previously observed complex between SD8 and GyrB
is ~1000-fold weaker than the interaction with GyrA.
© 2014 The Authors. Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
DNA topoisomerases are enzymes that control
the topological state of DNA in cells [1–3]. These
enzymes are divided into two types depending on
whether their mechanism of action involves break-
ing one (type I) or both (type II) strands of DNA. DNA
topoisomerases are capable of performing DNA
supercoiling and relaxation, catenation and decate-
nation, and knotting and unknotting, as a result of
their ability to pass one segment of DNA through a
break in another. DNA gyrase is the only type II
topoisomerase capable of catalyzing DNA super-
coiling, in a reaction driven by ATP hydrolysis [4].
DNA gyrase consists of two subunits, GyrA and
GyrB (97 kDaand90 kDa, respectively, inEscherichia
coli), forming an A2B2 complex in the active enzyme.
The N-terminal domain of GyrB is the site of ATP
hydrolysis, while DNA cleavage and strand passage
occur at the interface between the C-terminal domain
of GyrB and the N-terminal domain of GyrA. Thisuthors. Elsevier Ltd. This is an open access
rg/licenses/by/3.0/).interface is known as the “DNA gate”; a second
interface in GyrA via which the passed DNA segment
leaves the protein is termed the “exit gate” [5,6].
Crucially, DNAgyrase is essential for all bacteria, but
not found in humans, making it an ideal target for
antibiotics [4,7,8], as illustrated by thehighly successful
fluoroquinolones [9,10]. Aminocoumarins, such as
novobiocin and clorobiocin, are another class of
well-characterized DNA gyrase inhibitors [11,12] but
are less clinically successful because of toxicity and
solubility issues. Simocyclinone D8 (SD8) is a bifunc-
tional antibiotic isolated fromStreptomyces antibioticus
Tü 6040 [13–16] that consists of a chlorinated
aminocoumarin moiety linked to an angucyclic polyke-
tide via a tetraene linker and a D-olivose sugar. In
contrast to other aminocoumarins, such as novobiocin,
that bind to the GyrB N-terminal domain and inhibit
ATPase activity, SD8 binds to the GyrA N-terminal
domain and prevents the binding of DNA [17], although
there is some evidence that SD8 can also bind to the
C-terminal domain of GyrB [18].article under the CC BY license
J. Mol. Biol. (2014) 426, 2023–2033
Fig. 1. Orthogonal views of biological dimers of the GyrA55 crystal structures presented in this work. (a) Two of the four
monomers of apoGyrA55 that comprise the ASU. (b) One monomer from the ASU of the GyrA55–SD8 complex (blue) with
the crystallographic symmetry-related molecule with which it forms the biological dimer (gray). The proteins are depicted in
cartoon representation with a semitransparent surface and the SD8molecules are shown as magenta or black sticks in the
ASU or symmetry-related monomer, respectively.
2024 A New Crystal Structure of Simocyclinone D8The interaction between DNA gyrase and SD8
has been well studied [17–21], including the crystal
structure of a complex formed between a 59-kDa
N-terminal domain (NTD) fragment of the E. coli
gyrase A subunit (GyrA59) and SD8 [21]. This
structure revealed two binding pockets that separately
accommodate the aminocoumarin and polyketide
moieties of SD8, forming a cross-linked GyrA59
tetramer in the crystal. The existence of the tetrameric
species was identified in solution by both analytical
ultracentrifugation and mass spectrometry under
similar protein-to-ligand ratios as those used to obtainFig. 2. Details of the SD8-binding site. (a) Orthogonal views
contouredat 1.5 σ and superposedon the final coordinates of the
the SD8 tetraene linker. (b) Schematic figure detailing protein–lig
represent hydrogen bonds, blue lines represent residues with
molecules. SD8 is colored black, and residues from the twomono
theGyrA55–SD8-binding sites, the upper panel displays the prot
binding pockets, while the lower panel shows the specific resid
associated water molecules as red spheres, and hydrogen-bo
indicate the position of helix 4 in each monomer.crystals, confirming that it was not simply a crystallo-
graphic artifact [21]. Further analysis using mass
spectrometry showed that the major solution-state
species at lower ligand concentrations is the GyrA59
dimer with one or two SD8 ligands bound, leading to
the proposition (and modeling) of SD8 binding to
GyrA59 in an alternative conformation that makes use
of binding pockets within a GyrA homodimer rather
than bridging between dimers [18]. The present work
tests the validity of this modeled binding conformation
and sheds new light on the mechanism of inhibition of
DNA gyrase by SD8.of simulated annealing omit electron density map for SD8
ligand. The redarrow indicates the position of the cisbond in
and interactions in the GyrA55–SD8 complex. Broken lines
hydrophobic interactions, and blue circles represent water
mers are colored red andgreen, respectively. (c)Close-up of
ein with a surface representation to highlight the shape of the
ues that bind SD8. Residues are depicted as yellow sticks,
nding interactions with black broken lines and red arrows
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Construction and properties of a 55-kDa GyrA
N-terminal domain fragment
A new GyrA NTD fragment was constructed with a
view of obtaining a crystal structure of SD8 bound to
GyrA in an alternative conformation that would be
representative of the situation at lower ligand
concentrations. This smaller 55-kDa NTD fragment
of GyrA (GyrA55), comprising residues 30–522 of
the 875-amino-acid wild-type sequence (compared
with residues 2–522 for GyrA59), crucially lacks
residues spanning Leu17 to Asp23 that have been
identified as providing 10 of the 12 protein–protein
hydrogen bonds responsible for stabilizing the
tetramer at the dimer–dimer interface in the crystal
structure of the GyrA59–SD8 complex [21]. This
55-kDa fragment also lacks the N-terminal α-helix
(α-helix 1), but to allow easier comparisons with the
work on the 59-kDa fragment, the same numbering
of α-helices is used; that is, the N-terminal helix in the
GyrA55 structures is referred to as α-helix 2.
The circular dichroism (CD) spectrum of GyrA55
confirmed that the protein is folded and is consistent
with the spectrum obtained for GyrA59 (Fig. S1).
Isothermal titration calorimetry (ITC) showed that
GyrA55 is still capable of binding SD8, yielding binding
parameters that are consistent with those previously
determined for GyrA59 (Fig. S2) [17].
Crystal structures of apoGyrA55 and the
GyrA55–SD8 complex
The 1.9-Å-resolution apoGyrA55 structure contains
four GyrA55 monomers in the asymmetric unit (ASU)
(Fig. S3), forming two biologically relevant homodi-
mers, an example of which can be seen in Fig. 1a.
Comparisons within this structure reveal some confor-
mational flexibility, with overall RMSD values up to
1.28 Å for monomer–monomer superpositions and up
to 1.37 Å for dimer–dimer superpositions. Superposi-
tion of each homodimer with a homodimer generated
from the apoGyrA59 [22] crystal structure (which has a
single monomer in the ASU) gives RMSD values of
0.87 and 1.20 Å, indicating that there is less variation
across these two structures thanwithin the apoGyrA55
structure.
The 2.05-Å-resolution GyrA55–SD8 complex
structure contains two GyrA55 monomers in the
ASU, although they do not form the biologically
relevant homodimer. Instead, two distinct homodi-
mers can be generated from these monomers by the
addition of crystallographic symmetry-related mono-
mers (Fig. S4). One of the resultant homodimers
(Fig. 1b) binds two crystallographically equivalent
SD8 molecules in a novel conformation (Fig. 2).
However, SD8 binding to the second homodimer iscompromised by crystal packing; the first homodimer
would otherwise clash with the olivose moiety of a
similarly bound SD8 molecule. Nevertheless, there
is some positive difference electron density in the
vicinity of the aminocoumarin-binding pocket of dimer
2, suggestive of a partially ordered SD8 ligand
(Fig. S5). The two monomers within the ASU are
closely superposable (overall RMSD value of 0.33 Å),
while the crystallographically generated dimers show
larger differences (overall RMSD value of 1.23 Å),
which is perhaps largely a consequence of variations
in the flexing of the long α-helices of the coiled-coil
domains that link the exit and DNA gates. The sub-
sequent analysis will focus mainly on the fully ligand-
bound dimer.
The conformation of the SD8 in GyrA55–SD8 is
significantly different to that observed in the previous
study [21], principally because it is bound entirely
within one GyrA55 homodimer. The polyketide
moiety has shifted to a position where it spans the
interface between the two GyrA monomers, with
SD8 forming hydrogen-bonding interactions with
residues from eachmonomer, specifically as follows:
direct hydrogen-bonding interactions with His80,
Gly81, and Met120 (from the adjacent monomer)
and indirect hydrogen-bonding interactions (via
water molecules) with Pro79 and Asp87 (from the
adjacent monomer) (Fig. 2b and c). The aminocou-
marin-binding pocket is essentially the same as that
observed for the GyrA59–SD8 complex, but its
orientation in the binding pocket is different (Fig. 3).
The aminocoumarin moiety is bound to the protein
through hydrogen-bonding interactions with Lys42,
His45, Arg91, and Ser172 and hydrophobic contacts
with Val44. When overlaid, the tetraene linkers of the
GyrA59–SD8 and GyrA55–SD8 complex structures
exit the aminocoumarin pocket at an angle of ~70°
with respect to one another (Fig. 3). In the latter, the
tetraene linker actually follows a similar path to that
of the intra-dimer conformation proposed in the
previous study [21], although it is more remote from
α-helix 4 and does not interact with it at all (Fig. 2c).
Additionally, there are no lobes of additional electron
density adjacent to the polyketide moiety, which
were modeled as Mg2+ in the GyrA59–SD8 complex.
In order to accommodate SD8 in this new binding
configuration, a single cis bond is required in the
tetraene linker adjacent to the ester linkage with the
olivose and is fully consistent with the observed
electron density (Fig. 2a). This cis bond introduces a
distinctive kink in the antibiotic such that the polyketide
moieties of the symmetry-related molecules are
directed toward one another giving a closest inter-
atomic distance of only 4.6 Å.
Superposition of each GyrA55–SD8 with each
apoGyrA55 dimer gives overall RMSD values below
1.44 Å, while values for all possible monomer–
monomer comparisons did not exceed 1.07 Å, indi-
cating that there are nomajor conformational changes
Fig. 3. A comparison between the intra-dimer binding
conformations of SD8 from the X-ray structure of the
GyrA55–SD8 complex presented here (magenta), the inter-
dimer SD8 binding conformation from the X-ray structure of
the GyrA59–SD8 complex (green; two SD8 molecules
shown) [21], and the proposed intra-monomer binding
model that links the polyketide and aminocoumarin-binding
sites that were observed in the same monomer of the latter
X-ray structure (yellow) [18]. In the GyrA59–SD8 complex
structure, the protruding polyketide and aminocoumarin
moieties are accommodated in binding pockets from a
second GyrA59 homodimer (not shown). The semitranspar-
ent protein surface corresponds to theGyrA55–SD8 complex
crystal structure.
2027A New Crystal Structure of Simocyclinone D8in the 55-kDa GyrA fragment upon SD8 binding. The
only significant change is that the N-terminal end of
α-helix 3 partially unwinds (it becomes two residues
shorter), allowing the protein main chain in this regionFig. 4. Conformational changes at the SD8-binding sites
movement of Arg91 in the aminocoumarin pocket of GyrA55–
changes in the following loop in GyrA55–SD8 (His80–Ser83) tha
GyrA55–SD8 and apoGyrA55 are colored blue and green, resp
and the side chains of key residues from each structure are repto move in order to accommodate the polyketide
moiety of one SD8molecule and, in so doing, projects
the side chain of Asp87 toward the symmetry-related
SD8 molecule, such that it hydrogen bonds, via a
water molecule, to the ester group connecting the
tetraene linker to the olivose sugar. As part of this
backbone rearrangement, the plane of the His80–
Gly81 peptide bond twists through ~90° to allow
hydrogen bonding of themain chain amide of Gly81 to
the epoxide group of the polyketidemoiety in the same
SD8 molecule. Additionally, there are a number of
side-chain rearrangements around the SD8-binding
site, but most of these are relatively minor, the
exception being Arg91, which is disordered in the
apoGyrA55 structure, with either no clear density for
the guanidinium group and/or high temperature
factors in each of the four monomers, suggesting
that it is highly mobile in the absence of SD8 (Fig. 4).
Re-evaluation of GyrA mutant data
In the previous crystallographic study of the GyrA–
SD8 interaction [21], a number of point mutants were
generated to probe the protein–ligand interaction.
The effects of many of these mutations could be
rationalized with reference to the structure of the
GyrA59–SD8 complex, but others could not be
adequately explained. These data were re-evaluated
in the context of the GyrA55–SD8 complex structure.
Mutations to Arg32, Arg47 (identified as binding
the polyketide moiety of SD8 in the GyrA59–SD8
complex crystal structure), and Asn165 (identified as
binding the aminocoumarin moiety of SD8 in the
GyrA59–SD8 complex crystal structure) had either
no increase in resistance to SD8 in DNA supercoilingbetween GyrA55–SD8 and apoGyrA55. Specifically, the
SD8, the partial unwinding of helix 4, and conformational
t prevent clashes and aid binding with the polyketidemoiety.
ectively; SD8 molecules are represented by magenta sticks,
resented by sticks and helices 4 as filled cartoons.
2028 A New Crystal Structure of Simocyclinone D8assays or no change in binding characteristics, as
determined by surface-plasmon resonance, when
compared to wild-type GyrA [21]. The change in the
SD8 orientation in GyrA55–SD8 repositions the poly-
ketide moiety away from Arg32 and Arg47 (Arg47 is
6.3 Å from SD8); it also moves the aminocoumarin
moiety away fromAsn165 (Asn165 is 6.6 Å fromSD8),
making any interactionswith any of these residues very
unlikely.
Conversely, mutations to Gly81 and Asp87 were
found to confer resistance to SD8 (identified by
sequencing SD8-resistant mutants) despite no clear
role for these residues in the stabilization of SD8 in
the GyrA59–SD8 complex crystal structure. These
mutations are readily interpretable with reference to
the GyrA55–SD8 structure, since Gly81 makes direct
contact with the polyketide moiety of SD8 and Asp87
makes indirect contact with the polyketide moiety of
the symmetry-related SD8 molecule via a water
molecule (Fig. 2b and c).
To further test the validity of the intra-dimer
binding mode of SD8 observed in the GyrA55–SD8
complex, we made three additional potentially disrup-
tive mutations: M120P in the polyketide pocket, K42A
in the aminocoumarin-binding pocket, and A84R in
α-helix 4 that runs parallel with the tetraene linker. The
M120P and K42A mutants resulted in 60- and 50-fold
increases in resistance to SD8, respectively, which
tallies with the loss of key hydrogen bonds. Con-
versely, the A84R mutant showed little or no increase
in resistance to SD8, but this could be rationalized by
the longer side chain adopting a conformation thatTable 1. Summary of SD8 resistance data for GyrA mutants
Type of mutant Mutation Relative IC50 (supe
compared to wild-ty
Resistance predicted based
on GyrA59–SD8, but not
observeda
Arg32 → Ala Inactive; surface-p
resonance show
change in SD8 b
Arg47 → Ala No change
Asn165 → Ala No change
Resistance not predicted based
on GyrA59–SD8, but was
observeda
Gly81 → Ser 40-fold increa
Asp87 → Tyr 57-fold increa
Resistance predicted based on
GyrA59–SD8, and observeda
His80 → Ala 230-fold increa
His45 → Ala 9-fold increas
Arg91 → Ala 20-fold increa
Resistance predicted based on
GyrA55–SD8, and observedb
Met120 → Pro 60-fold increa
Ala84 → Arg 2 fold-increas
Lys42 → Ala 50-fold increa
Quinolone-resistant mutationsa Ser83 → Trp 10-fold increa
Ala84 → Pro 38-fold increa
All mutations were made with full-length GyrA.
Distances quoted are closest atom–atom contacts.
AC, aminocoumarin moiety; PK, polyketide moiety; OL, olivose sugar;
a Mutants generated and tested in a previous study [21].
b Mutants generated and tested in this work.does not impinge on the SD8-binding site. Sample
data are shown in Fig. S6; a full analysis of how each
mutant affects the GyrA–SD8 complex is given in
Table 1. Overall we conclude that the SD8 orientation
observed in the GyrA55–SD8 structure is fully
representative of the in vitro (and likely the in vivo)
binding mode of SD8 to gyrase at physiologically
relevant concentrations due to the strong correlation
with all the available mutant data.
Comparison with existing type II topoisomerase
structures leading to a proposition of the
inhibitory mechanism of SD8
Wendorff et al. analyzed all 22 type II topoisom-
erase structures available in the Protein Data Bank
at the time of publication and found that there were 6
distinct sub-groups based on the exit-gate position,
as well as the binding of DNA or drug molecules [23].
The structures presented in this work fit with the
group of type II topoisomerase structures that have a
closed exit gate and no DNA bound; that is, they are
consistent with the existing structures. Observing
the differences between apo and DNA-bound type II
topoisomerases in these groupings highlights con-
served conformational changes that occur at the
DNA gate to facilitate DNA binding.
These comparisons also allow us to speculate on
the mechanism by which SD8 blocks DNA binding to
gyrase, by comparing the GyrA55–SD8 complex
structure with gyrase structures in complex with DNA.
The positioning of SD8 across the dimer interfacercoiling)
pe GyrA
Context in
GyrA59–SD8
Context in
GyrA55–SD8
lasmon
s no
inding
H-bond to PK Absent from model;
superposition with GyrA59
indicates that it
is remote from SD8
2 H-bonds to PK 6.3 Å from TL
H-bond to AC 6.1 Å from AC
se Close to OL H-bond to PK
se 7.0 Å from TL H-bond to PK via water
se Aromatic stacking with PK H-bond to PK
e Aromatic stacking with AC H-bond to AC
se H-bond to AC H-bond to AC
se Remote from SD8 H-bond to PK
e 7.9 Å from TL 4.0 Å from TL
se H-bond to TL H-bond to TL
se 8.3 Å from PK Disrupt PK binding
se Disruption to α-helix 4 Disruption to α-helix 4
TL, tetraene linker.
2029A New Crystal Structure of Simocyclinone D8effectively “staples” the dimer closed, which not only
has the effect of preventing the DNA gate from
opening for strand passage but also precludes the
observed conformational changes that need to occur
around the DNA gate to allow DNA binding. Specif-
ically, the interactions of Asp87 and Gly81 with SD8
would prevent the necessary movement of α-helix 4;
the interaction between Met120 and SD8 would
prevent the loop containing the catalytic tyrosine
(Tyr122) from orienting itself correctly with respect to
the DNA, and the interaction of Arg91 (also found on
α-helix 4) with the aminocoumarin moiety of SD8
would prevent Arg91 from stabilizing the GyrA–DNA
complex (Fig. 5).
ITC analysis of SD8 binding to gyrase
ITC analysis was carried out to further charac-
terize the binding properties of SD8 to gyrase.
An interaction was observed when SD8 was
injected into a GyrA55 solution, yielding a binding
constant of 44 nM and indicating an approximate
1:1 stoichiometry (Fig. S2a). These parameters
are consistent with those previously determined
for GyrA59 [17].
Work by Sissi et al. suggested a new SD8-binding
site in GyrB [20]. This was based on the results of CD
experiments, which showed that SD8 affects the
thermal transitions of GyrB as well as GyrA, and
proteolytic digestion studies, which found that SD8
affects the proteolysis pattern resulting from the
digestion of GyrB47 (the C-terminal domain of GyrB)Fig. 5. A comparison of the DNA gates from GyrA55–SD8 (li
DNA and GSK299423 (ligand not shown) (yellow) [24]. The p
representation, with regions of interest depicted as filled cart
sticks, with the latter in magenta.by trypsin. We have used ITC to further explore the
binding of SD8 to GyrB.
An interaction was observed when SD8 was
injected into a GyrB solution (data not shown). An
interaction was not observed with GyrB43 (N-terminal
GyrB domain) but was observed with GyrB47
(C-terminal GyrB domain), yielding a binding constant
of 46 μM and indicating an approximate 1:1 stoichi-
ometry (Fig. S2b). This finding is consistent with that of
Sissi et al., who observed an SD8-binding site in the
C-terminal domain of GyrB [20]. However, the
substantially higher affinity of SD8 for GyrA over
GyrB (approximately 1000-fold in this study) would
suggest that GyrA is the primary target for SD8 and
that the interactionwithGyrBmay be an in vitro artifact
that is only manifested in the absence of GyrA. These
observations may correlate with the promiscuous
binding we have observed with the polyketide moiety
of SD8 in the GyrA59–SD8 and GyrA55–SD8
complex structures.
Conclusion and summary
In this work we have presented a new structure for
an N-terminal GyrA–SD8 complex (GyrA55–SD8)
that is significantly different to that observed in the
previous study [21], principally because the antibiotic
is bound entirely within one GyrA55 homodimer. We
have shown, through evaluation of mutant data, that
this new structure is more likely to be representative
of the mode of action of SD8 on DNA gyrase and,
through comparisons with existing type IIght blue) and Staphylococcus aureusGyrA in complex with
rotein and DNA are depicted in semitransparent cartoon
oon. Key residues and the SD8 molecules are shown as
2030 A New Crystal Structure of Simocyclinone D8topoisomerase structures, provides a molecular
level explanation of the mechanism of action of
SD8. In addition, we have also presented the
high-resolution structure of apoGyrA55 that has
allowed us to describe specific conformational
changes brought on by the action of SD8 binding
to gyrase.Table 2. Summary of GyrA55 X-ray data and model
parameters
Data set apoGyrA55 GyrA55–SD8
Data collection
Space group P1 C2
Cell parameters
a, b, c (Å) 93.57, 95.53,
95.89
160.82, 96.05,
112.35
α, β, γ (°) 105.16, 118.81,
103.42
90.00, 132.72,
90.00
Solvent content (%) 59.0 57.6
Beamlinea i24 i04-1
Wavelength (Å) 0.9686 0.9173
Resolution rangeb (Å) 81.51–1.90 41.51–2.05
(1.95–1.90) (2.10–2.05)
Unique reflectionsb 194,509 (14,158) 77,820 (5648)
Completenessb (%) 97.0 (94.7) 99.0 (98.1)
Multiplicityb 2.9 (2.6) 7.2 (5.4)
Rmerge
b,c 0.067 (0.486) 0.088 (0.895)
Rmeas
a,c 0.095 (0.687) 0.094 (0.996)
CC½
a,d 0.993 (0.598) 0.999 (0.533)
〈I〉/〈σI〉b 11.0 (2.7) 15.0 (2.0)
Wilson B value (Å2) 23.6 30.3
Refinement
Rcryst
d (basedon 95%of data) 0.169 0.196
Rfree
d (based on 5% of data) 0.189 0.225
Coordinate error estimatee
(based on Rfree; Å)
0.109 0.146
Ramachandran favored/
allowed/disallowedf (%)
98.4/1.4/0.2 97.9/1.4/0.7
RMSD bond distances (Å) 0.013 0.015
RMSD bond angles (°) 1.502 1.643
Contents of model (molecules/non-hydrogen atoms)
Protein 1942/15,016 885/6784
SD8 — 1/66
Water molecules 1056 284
Average temperature factors (Å2)
Protein 31.9 42.6
SD8 — 43.1
Waters 37.3 40.7
Overall 32.3 42.6
PDB accession code 4CKK 4CKL
a i24 and i04-1 are beamlines at the Diamond Light Source
(Oxfordshire, UK).
b The figures in parentheses indicate the values for the
outer-resolution shell.
c Rmerge = ∑hkl∑i|Ii(hkl) − 〈I(hkl)〉|∑hkl∑iIi(hlk), where Ii(hlk) is the
ith observation of reflection hkl and 〈I(hkl)〉 is the weighted
average intensity for all observations i of reflections hkl.
d The R-factors Rcryst and Rfree are calculated as follows: R =
∑(|Fobs − Fcalc|)/∑|Fobs| × 100, where Fobs and Fcalc are the
observed and calculated structure factor amplitudes, respectively.
e Estimate of the overall coordinate errors calculated in REFMAC5
based on Rfree.
f Calculated using MolProbity [33].Materials and Methods
Expression and purification of proteins
The N-terminal 55-kDa fragment (exact molecular mass,
55,390.5 Da) of E. coli DNA gyrase subunit A (GyrA55),
comprising residues 30–522of the875-amino-acidwild-type
sequence (UniProtKB/Swiss-Prot entry P0AES4), and the
GyrA59 protein were produced using a modification of the
previously published procedure [21,25]. GyrA mutants and
GyrB and GyrB fragments were expressed and purified as
described previously [26–28].
Crystallization and X-ray data collection
A purified GyrA55 sample, at a concentration of 10 mg/
ml in TGED buffer [50 mM Tris–HCl (pH 7.5), 1 mM
ethylenediaminetetraacetic acid (EDTA), 1 mM DTT, and
10% (v/v) glycerol], was used for crystallization. For the
apoGyrA55 structure, crystals were grown in hanging
drops composed of 1.5 μl protein solution and 1.5 μl
reservoir solution [0.1 M Tris–HCl (pH 8.5) and 30% (v/v)
polyethylene glycol 300] equilibrated against 1 ml reser-
voir solution at 20 °C. The crystals were mounted in
LithoLoops (Molecular Dimensions) and cooled by plung-
ing into liquid nitrogen without the need for further
cryoprotection. For the GyrA55–SD8 structure, crystals
were grown in sitting drops composed of 0.3 μl protein
solution and 0.3 μl reservoir solution [0.1 M 4-morpholi-
neethanesulfonic acid (pH 6.5) and 40% (v/v) polyethyl-
ene glycol 200] equilibrated against 50 μl reservoir
solution at 20 °C. Prior to mounting, crystals were soaked
overnight in the crystallization solution, with the addition of
1 mM SD8 in 10% (v/v) DMSO (final concentration) and
could also be cooled by plunging into liquid nitrogen
without the need for further cryoprotection. Diffraction
data were recorded at the Diamond Light Source on
beamline i24 with a Pilatus 6M detector for the apoGyrA55
structure and on beamline i04-1 with a Pilatus 2M detector
for the GyrA55–SD8 structure. The resultant data sets
were processed using Xia2 [29] and the statistics are
summarized in Table 2.
Structure determination and refinement
A monomer from the existing 2.6-Å-resolution crystal
structure of GyrA59–SD8 complex (PDB accession code
2Y3P [21]) was used as a search model for molecular
replacement with the apoGyrA55 data after stripping away
all solvent molecules and the ligand. Molecular replacement
was performed using Phaser [30]. Four independent mole-
cules were located in the ASU. Solvent content estimationsbased on four GyrA55 monomers per ASU gave a value of
59.0%. Manual rebuilding of this initial model was
performed with Coot [31], and this was alternated with
cycles of restrained refinement with REFMAC5 [32].
Non-crystallographic asymmetry restraints were employed
and, in the final stages, TLS refinement was usedwith a total
2031A New Crystal Structure of Simocyclinone D8of 24 TLS domains, which were defined using the TLS
motion determination server† [34]. The statistics of the final
model are summarized in Table 2.
A monomer from this 1.9-Å-resolution crystal structure of
apoGyrA55 was used as a search model for molecular
replacement with the GyrA55–SD8 data after stripping
away all solvent molecules. Two independent molecules
were located in the ASU (these monomers did not form the
biological dimer, but the biological dimers could be
generated via crystallographic symmetry), and solvent
content estimations based on two GyrA55 monomers
per ASU gave a value of 57.8%. The same refinement
techniques were applied to this data set, and a total of 16
TLS domains were used in the final stages of the
procedure. Residual electron density was apparent for
one complete SD8 molecule in one monomer of the ASU,
and some density was seen in the vicinity of the
aminocoumarin pocket of the other monomer, but this
was not well resolved and consequently was left vacant.
The statistics of the final model are summarized in Table 2.
Mutagenesis
Site-directed mutants were made in full-length GyrA
using the Phusion Site-Directed Mutagenesis kit (Thermo
Scientific) according to the manufacturer's protocol, using
plasmid pPH3 [35]. The mutations were confirmed by
sequencing (Genome Enterprise Ltd.).DNA supercoiling assay
Gyrase supercoiling assayswere performed as described
previously [36]. Samples (30 μl) containing gyrase (22 nM)
and 0.5 μg of relaxed pBR322 DNA (6 nM) were incubated
at 37 °C for 30–90 min (depending on the GyrA used:
90 min for the less active K42A and M120P GyrA mutants;
30 min for all others) in the presenceof 1 mMATP. TheDNA
was prepared for electrophoresis by the addition of 30 μl of
phenol-chloroform-isoamyl alcohol (25:24:1), 15 μl of 40%
(w/v) sucrose, 0.1 M Tris–HCl (pH 8), 0.1 M EDTA, and
0.5 mg/ml bromophenol blue, brief vortexing and centrifu-
gation (15,700g, 5 min). The blue upper phases of the
products were analyzed on 1% (w/v) agarose gels. To
determine approximate IC50 values for SD8, we carried out
supercoiling assays including a range of SD8 concentra-
tions. Gels were analyzed and the IC50 determined by visual
inspection of the intensity of the supercoiledDNAband in the
SD8 containing lanes, relative to the no drug control lane, as
described previously [19].Isothermal titration calorimetry
Enthalpy values were measured by using an iTC200
isothermal titration calorimeter (Microcal, Milton Keynes,
United Kingdom). Gyrase subunits and domains (GyrA55,
GyrB43, and GyrB47) were dialyzed extensively against
binding buffer [50 mM Tris–HCl (pH 7.5), 1 mM EDTA,
and 100 mM KCl]. During the titration, the protein (200 μl,
at 5–15 μM) was added to the sample cell, and 27
successive aliquots of SD8 (at 100–250 μM) [1.5 μl
volumes except for the first one (0.5 μl)] were injected at
2-min intervals. All titrations were carried out at 25 °C. Aconstant DMSO concentration of 3% (v/v) (obtained by
addition of DMSO to protein and SD8 samples) was used
to aid SD8 solubility. The upper limit of SD8 concentration
was 250 μM due to the poor solubility of the drug at higher
concentrations. Data were analyzed by nonlinear regres-
sion using a single-site binding model with Origin software
(Microcal), which yielded independent values for Kd.
CD spectroscopy
CD spectroscopy experiments were performed using a
Chirascan-Plus CD spectrophotometer (Applied Photo-
physics). Proteins at concentrations of approximately
10 mg/ml (in TGED buffer) were diluted to 0.25 mg/ml in
20 mM potassium phosphate (pH 7.2). CD measurements
were carried out in a quartz glass cuvette with a 0.5-mm
path length at 20 °C. Each CD spectrum is the average of
4 scans collected between 190 and 260 nm, using a
bandwidth of 2.0 nm, a step size of 0.5 nm, and time points
of 1 per second. Secondary structure assignments were
made using the DichroWeb server, employing the Cdsstr
method with reference set 7 [37,38].
Accession numbers
Coordinates and structure factors for the apoGyrA55
and GyrA55–SD8 structures described herein have been
deposited in the Protein Data Bank with accession codes
4CKK and 4CKL, respectively.Acknowledgements
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